구조모아 (StructureMoa)항암 chemical structure spider web
방문Ferring Pharmaceuticals
분석
큐레이션 브리핑
방광내 아데노바이러스 IFNα2b 유전자치료. BCG-unresponsive NMIBC CR. 펨브로·방광절제와 라인 경쟁.
경쟁 포지션: Gene therapy option vs pembrolizumab / radical cystectomy
기전. Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
IFNα2b (adenoviral)
High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
US
Approved
adstiladrin · nadofaragene firadenovec · Adstiladrin · nadofaragene firadenovec-vncg · rAd-IFNα/Syn3
2026-09-10
Data Confidence · High
Development Signal · Established
Adenoviral gene therapy
rAd-IFNα/Syn3
humanized mouse model
Local bladder gene delivery avoiding systemic AAV exposure
구조화 데이터
Local bladder gene delivery avoiding systemic AAV exposure
downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo
rAd-IFNα/Syn3
IFNα2b (adenoviral) · Complete response at 3/6/12 months (cystoscopy, cytology, biopsy).
Local urinary AEs, discharge
Gene therapy option vs pembrolizumab / radical cystectomy
BCG-unresponsive CIS ± papillary NMIBC
Intravesical instillation
q3 months (label)
Complete response rate in CIS
Local urinary AEs, discharge
Gene therapy option vs pembrolizumab / radical cystectomy
Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC.
Macrophages showed upregulation of PD1/PD-L1 pathways along with downregulation of macrophage activation
apoptosis and reduces tumor volume by 91% after 1 month
Complete response at 3/6/12 months (cystoscopy, cytology, biopsy).
downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo
구조화 데이터
syngeneic MB49 orthotopic murine bladder cancer model
mouse
pharmacodynamic
구조화 데이터
차트 로드 중…
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (NMIBC)
APPROVAL · 2022년 12월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Ferring Pharmaceuticals
분석
큐레이션 브리핑
방광내 아데노바이러스 IFNα2b 유전자치료. BCG-unresponsive NMIBC CR. 펨브로·방광절제와 라인 경쟁.
경쟁 포지션: Gene therapy option vs pembrolizumab / radical cystectomy
기전. Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
IFNα2b (adenoviral)
High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
US
Approved
adstiladrin · nadofaragene firadenovec · Adstiladrin · nadofaragene firadenovec-vncg · rAd-IFNα/Syn3
2026-09-10
Data Confidence · High
Development Signal · Established
Adenoviral gene therapy
rAd-IFNα/Syn3
humanized mouse model
Local bladder gene delivery avoiding systemic AAV exposure
구조화 데이터
Local bladder gene delivery avoiding systemic AAV exposure
downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo
rAd-IFNα/Syn3
IFNα2b (adenoviral) · Complete response at 3/6/12 months (cystoscopy, cytology, biopsy).
Local urinary AEs, discharge
Gene therapy option vs pembrolizumab / radical cystectomy
BCG-unresponsive CIS ± papillary NMIBC
Intravesical instillation
q3 months (label)
Complete response rate in CIS
Local urinary AEs, discharge
Gene therapy option vs pembrolizumab / radical cystectomy
Nadofaragene firadenovec is a non-replicating adenoviral vector delivering IFNα2b cDNA to bladder urothelium for BCG-unresponsive NMIBC.
Macrophages showed upregulation of PD1/PD-L1 pathways along with downregulation of macrophage activation
apoptosis and reduces tumor volume by 91% after 1 month
Complete response at 3/6/12 months (cystoscopy, cytology, biopsy).
downregulation of mTOR and STAT3 at the single-cell resolution, both in vitro and in vivo
구조화 데이터
syngeneic MB49 orthotopic murine bladder cancer model
mouse
pharmacodynamic
구조화 데이터
차트 로드 중…
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (NMIBC)
APPROVAL · 2022년 12월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.